P040 | REAL-WORLD EXPERIENCE WITH BISPECIFIC ANTIBODY EPCORITAMAB IN RELAPSED/REFRACTORY DLBCL: A MULTICENTRIC RETROSPECTIVE ANALYSIS

Background: Epcoritamab is approved for relapsed/refractory DLBCL from the third line onward. Pivotal trial results showed high efficacy and good safety. However, real-world data are limited, with some studies showing less favorable outcomes. This retrospective analysis evaluates its efficacy and s...

Полное описание

Библиографические подробности

Главные авторы:	M. Porrazzo, V. Tarantino, G. Catalano, R. Scalone, G.A. Milone, G. Amato, M. Rossi, L. Scalise, A. Greco, V. Di Martina, M. Martino, L. Castagna, C. Patti
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Ferrata Storti Foundation 2025-09-01
Серии:	Haematologica
Online-ссылка:	https://haematologica.org/article/view/12537
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!